TMCnet News

Research and Markets: AIDS-Related Opportunistic Infections - Pipeline Review, Q2 2011 Includes Special Features on Late-stage and Discontinued Projects
[July 05, 2011]

Research and Markets: AIDS-Related Opportunistic Infections - Pipeline Review, Q2 2011 Includes Special Features on Late-stage and Discontinued Projects


DUBLIN --(Business Wire)--

Research and Markets(http://www.researchandmarkets.com/research/4e655c/aidsrelated_oppor) has announced the addition of Global Markets Direct's new report "AIDS-Related Opportunistic Infections - Pipeline Review, Q2 2011" to their offering.

Global Markets Direct's, 'AIDS-Related Opportunistic Infections - Pipeline Review, Q2 2011', provides an overview of the AIDS-Related Opportunistic Infections therapeutic pipeline. This report provides information on the therapeutic development for AIDS-Related Opportunistic Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS-Related Opportunistic Infections. 'AIDS-Related Opportunistic Infections - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Copany/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

  • A snapshot of the global therapeutic scenario for AIDS-Related Opportunistic Infections.
  • A review of the AIDS-Related Opportunistic Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the AIDS-Related Opportunistic Infections pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy


  • Identify and understand important and diverse types of therapeutics under development for AIDS-Related Opportunistic Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding AIDS-Related Opportunistic Infections pipeline depth and focus of AIDS-Related Opportunistic Infections therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Topics Covered:

  • List of Tables
  • List of Figures
  • AIDS-Related Opportunistic Infections Overview
  • Therapeutics Development
  • An Overview of Pipeline Products for AIDS-Related Opportunistic Infections
  • AIDS-Related Opportunistic Infections Therapeutics under Investigation by Universities/Institutes
  • Late Stage Products
  • Comparative Analysis
  • Mid Clinical Stage Products
  • Comparative Analysis
  • AIDS-Related Opportunistic Infections Therapeutics - Products under Investigation by Universities/Institutes
  • AIDS-Related Opportunistic Infections - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • Trimetrexate Glucuronate + Leucovorin Calcium - Drug Profile
  • Hepatitis B Virus Vaccine + GM-CSF - Drug Profile
  • Intradermal HBV 1 course + Intramuscular HBV I Course - Drug Profile
  • Intradermal HBV 1 course + Intramuscular HBV I Course - Drug Profile
  • Pentamidine Isethionate - Drug Profile
  • Inactivated Influenza Vaccine - Drug Profile
  • Dapsone - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • AIDS-Related Opportunistic Infections Therapeutics - Discontinued Products

For more information visit http://www.researchandmarkets.com/research/4e655c/aidsrelated_oppor.


[ Back To TMCnet.com's Homepage ]